LabCentral offers a fertile environment in which visionaries can thrive

Board of Directors

Johannes Fruehauf (Cambridge Biolabs), Peter Parker (BioInnovation LLC), and Tim Rowe (Cambridge Innovation Center) have created LabCentral based on their own experiences as entrepreuneurs and that of countless others who have spent precious time and resources searching for and equipping appropriate startup lab space. Clearly, there is a glaring need for such a facility centered in and around Cambridge and Boston designed specifically for the life-sciences community.

  • Johannes Fruehauf, MD, PhD

    Co-founder, President

    CEO, Cambridge Biolabs and ViThera Pharma; Cofounder, Cequent Pharmaceuticals

    Johannes Fruehauf (MD PhD) has a background as a physician working in diverse health systems. In his 15+ years as a serial biotech entrepreneur, Dr. Fruehauf has dedicated much of his professional endeavors to the mission of re-defining life science entrepreneurship and building start-up ecosystems. 

    He is the Founder and President of LabCentral, the preeminent private/public partnership model for life science incubator space, while also serving as CEO for BioLabs, the largest provider of laboratory co-working space for startups nationwide. LabCentral and Biolabs currently are home for over 300 startups in 8 cities and companies started within this network now routinely account for over 20% of all Seed and Series A venture capital invested in life sciences in the US.

    Johannes is founder and General Partner of Mission BioCapital (MBC). In his role at MBC, he sources, diligences, and leads new life-science investment transactions and represents the fund on the board of a number of MBC portfolio companies.

    Dr. Fruehauf studied medicine in Germany and France, while also conducting field work in Africa (Zimbabwe and Guinea). He graduated from University of Frankfurt and received his doctorate from the University of Heidelberg. Johannes is the author of over 30 peer reviewed publications and is named inventor on 9 patents.

  • Peter Parker

    Co-founder, Director

    Managing General Partner, Mission BioCapital; Previously General Partner, Ampersand Ventures, and CEO, Cequent Pharma and Boston Heart Diagnostics

    Peter Parker is a co-founder and director of LabCentral.  In 2013, Johannes Fruehauf, Peter Parker, and Maggie O’toole created a vision for LabCentral and the resulting ecosystem which is still vibrant nearly a decade later.  Mr. Parker is active in company selection processes and organizes board activities. He is also Secretary of MainStPBC, Inc, LabCentral’s for-profit subsidiary which manages spaces at 238 and 610 Main St.   Outside of LabCentral, Mr. Parker conducts seed and early-stage life-sciences investing activities through Mission BioCapital based in Cambridge, Mass. Prior to LabCentral, Mr. Parker assisted the staff at MassChallenge where he was the healthcare/life sciences ‘Champion’ for five years. He is also a co-founder of BioLabs and several other local firms.  Peter spent almost two decades as a general partner at Ampersand Capital Partners, Wellesley, Mass. He has been a board member and investor in more than 35 life sciences companies.

  • John Harthorne


    CEO, MassChallenge; Bain & Company

    John Harthorne is the Founder & Managing Director of Two Lanterns Venture Partner, a $25M seed fund investing in US and Israeli software startups poised to create massive impact.

    Prior to launching Two Lanterns, John founded and then ran MassChallenge as CEO for a decade. MassChallenge is the most startup-friendly accelerator on the planet. No equity and not-for-profit, MassChallenge is obsessed with helping entrepreneurs across all industries. Through MassChallenge’s global network of accelerators in Boston, Israel, Switzerland, Mexico, Rhode Island, Austin and Houston, and unrivalled access to corporate partners, MassChallenge entrepreneurs are creating a massive impact - driving growth and creating value the world over. To date, 2,900+ MassChallenge alumni have raised over $8.5 billion of funding, have generated over $3.5 billion of revenue, and have created over 186,000 jobs.

    John earned his MBA from the MIT Sloan School of Management in 2007. While at school, John won Grand Prize in the 2007 MIT $100K Business Plan Competition and received the 2007 Patrick J. McGovern Award for impact on quality and visibility of entrepreneurship at MIT. The Boston Business Journal identified John as one of Boston's 50 Most Influential Business Leaders alongside the CEOs of Akamai Technologies, Blue Cross Blue Shield and the Boston Celtics. The World Economic Forum also elected John as a Young Global Leaders alongside Chelsea Clinton and Tony Hsieh, and Ernst & Young voted John as Social Entrepreneur of the Year in New England for 2013.

  • Steve Tregay

    Director, Chairman of the Board

    CEO, Forma Therapeutics; Novartis Venture Fund; Novartis Strategic Alliances

    Steve Tregay is the founder, president and CEO of FORMA Therapeutics, a company building a robust pipeline of transformative cancer therapeutics directed in areas such as tumor metabolism, epigenetics and protein-protein interactions. Prior to joining FORMA, Steven Tregay was a managing director for the $200 million Novartis Option Fund. He led the fund’s investments in and served on the board of directors of FORMA Therapeutics, Adenosine Therapeutics (acquired by Clinical Data: FRX) and Cequent Pharmaceuticals (acquired by Marina Biotech: MRNA). Prior to joining the venture group, he was the executive director and head of strategic alliances – Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research. He received his doctoral and master’s degrees in organic chemistry from Harvard University and a bachelor’s from Davidson College.

  • Susan Windham-Bannister, PhD, D.Sc


    CEO, Biomedical Growth Strategies

    Dr. Windham-Bannister received her B.A. from Wellesley College, a Doctorate in Health Policy and Management from the Florence Heller School at Brandeis University, and a Doctor of Science from Worcester Polytechnic Institute (honoris causa). She was a Post-Doctoral Fellow at Harvard University's John F. Kennedy School and a Fellow in the Center for Science and Policy (CSAP) at Cambridge University, Cambridge, England. She completed her doctoral work at the Heller School under a fellowship from the Ford Foundation.

    Dr. Windham-Bannister currently serves as president and CEO of Biomedical Growth Strategies, where she provides strategic advisory services to life-sciences initiatives in the U.S. and abroad.

    Previously, Dr. Windham-Bannister served as the president and CEO of the Massachusetts Life Sciences Center (MLSC), an economic development and investment agency dedicated to supporting the growth and development of the life-sciences in Massachusetts. As CEO, she managed a $1B fund designated to invest in biotechnology, pharmaceuticals, medical devices, medical diagnostics and bioinformatics/analytics. She is the first African American in the U.S. to lead a life-sciences focused innovation fund of this scale and was responsible for the MLSC's investment strategy, brand management, organizational development, and ROI. 

  • Jo Viney, PhD


    Founder, President and CEO, Seismic Therapeutic, Inc.

    Dr. Viney received her BSc in Biophysics at the University of East London and her PhD in Gut Immunology at the University of London (St Bartholomew’s Hospital Medical School). She went on to a Postdoctoral Research Fellowship at Imperial Cancer Research Fund (now Cancer Research UK), followed by a second Postdoctoral position at Genentech.

    Dr. Viney currently serves as the founder, president, and chief executive officer at a new biotechnology start-up – Seismic Therapeutic, the machine learning immunology company. Prior to Seismic Therapeutic, she was founder, president and CSO of Pandion Therapeutics, a company focused on modular biologics for treating autoimmune diseases. Pandion was acquired by Merck in 2021.

    Before Pandion, Dr. Viney served as Biogen’s Senior Vice President of Drug Discovery. Earlier in her career she was Amgen’s Executive Director for Inflammation Research and was the Director of Autoimmunity and Inflammation Research at Immunex prior to its acquisition by Amgen. In addition, she sits on the Board of Directors for Harpoon Therapeutics, Finch Therapeutics, and Graphite Bio. An advocate for diversity in the STEM field, Dr. Viney was also on the board and president of the non-profit, WEST (Women in the Enterprise of Science and Technology), which aims to help early career women reach their full potential.